The Download: testing six tech promises and biotech’s blind spots

Palmer Luckey and Ben Lamm announced on Thursday the launch of Warhound, a new defense technology startup that has secured $200 million in seed funding to develop genetically engineered dogs for the United States military. The company aims to produce custom-built canines designed for specific tactical roles, moving beyond traditional breeding methods to utilize advanced genetic modification and cloning techniques. Investors backing the initial round include Sequoia Capital, Joe Lonsdale’s 8VC, and In-Q-Tel, a venture capital firm originally established by the Central Intelligence Agency. The initiative represents a collaboration between two existing entities: Anduril Industries, the defense contractor co-founded by Luckey, and Colossal Biosciences, the biotechnology firm led by Lamm that has previously attempted to resurrect extinct species such as the woolly mammoth. Warhound intends to leverage Colossal’s genetics platform alongside Anduril’s defense technology infrastructure. The stated goal is to create dogs that are healthier, more durable, and possess enhanced physical capabilities compared to current standards. Lamm told TechCrunch that the enhancements target health, longevity, speed, agility, and olfactory sensitivity for tasks such as bomb detection. Currently, the U.S. Department of Defense maintains approximately 1,600 military working dogs. These animals are predominantly Belgian Malinois or German Shepherds, used primarily for detecting explosives and narcotics. According to figures cited in Warhound’s press materials, roughly 80 percent of these dogs are sourced from Europe, although some are bred domestically. The organization noted that fewer than half of the dogs entering the military’s rigorous training program successfully complete it. Warhound argues that domestic production of genetically optimized dogs would reduce reliance on a shrinking European supply chain and strengthen national security infrastructure. David Spirk, a former Marine Corps intelligence analyst who previously worked at Palantir focusing on expanding the company’s software footprint across the U.S. government, was named chief executive officer of the new venture. In a statement describing the project, company representatives framed the dogs as strategic assets comparable to critical minerals, asserting that the move would bolster America’s ability to protect its people and infrastructure. The dogs are intended to perform duties that are either too dangerous for humans or too complex for machines, including explosive detection and the search for specific objects or individuals. The technical approach involves using cells from selected foundation breeds, specifically the Belgian Malinois and German Shepherd, which are considered reliable working dogs. Colossal Biosciences researchers have identified these breeds as the strongest candidates for the base genome. The plan involves cultivating cells in a laboratory setting before editing the genetic code. The process entails adding genes that improve specific capabilities while removing those that might limit performance or predispose the animal to disease. Lamm described the resulting animal as a "new type of dog," distinct from simply cloning existing specimens. This effort follows previous work by Lamm’s company, Colossal, which last year produced three hybridized gray wolves with long, white hair. The company marketed these animals as "dire wolves," a species believed to have gone extinct approximately 10,000 years ago. However, skeptical scientists pointed out that the animals were genetically modified versions of extant wolves rather than true recreations of the extinct species. Similarly, critics may question whether Warhound’s output constitutes a genuinely new breed or a highly modified version of existing military dog types. Luckey, whose personal history includes being the brother-in-law of disgraced former Representative Matt Gaetz, has a track record of ambitious and sometimes controversial technological proposals. His portfolio includes concepts ranging from space exploration hardware to proposals involving oxytocin doping to influence marital stability. The involvement of investors with ties to the far-right political sphere, such as Peter Thiel-linked funds and 8VC, which shares leadership structures with Palantir, adds a layer of political association to the project. The timing of the announcement coincides with broader trends in Silicon Valley regarding genetic optimization. While some tech leaders pursue gene editing to address artificial intelligence threats or create "designer" children, Warhound applies similar principles to military applications. The company has stated that the dogs do not yet exist but hopes to begin production within two years. The project positions itself as a reshoring success for the U.S. defense sector, aiming to eliminate the need to import specialized working dogs from abroad. Reactions to the announcement highlight the intersection of biotechnology and warfare. Proponents view the potential for increased reliability and safety in military operations as a significant advantage. The dogs are projected to be more obedient, resilient, and capable partners for their handlers. Opponents and scientific observers raise questions about the ethical implications of designing animals for combat and the practical efficacy of genetic modifications in dynamic battlefield environments. The distinction between enhancing traits and creating fundamentally new biological entities remains a point of debate among experts. Warhound’s strategy relies on the assumption that genetic engineering can solve the logistical and biological challenges inherent in maintaining a large corps of working dogs. By controlling the genetic input, the company seeks to ensure consistent quality and capability across its entire output. This contrasts with traditional breeding programs, where variability in temperament and health is common. The integration of Anduril’s cybernetic augments and software systems suggests that the final product will combine biological enhancement with digital connectivity, providing real-time situational awareness on the battlefield. The funding structure indicates strong confidence from major venture capital players in the viability of the concept. The inclusion of both private equity giants and government-linked investment vehicles underscores the dual nature of the project as both a commercial enterprise and a national security initiative. As the company moves toward its two-year production target, attention will turn to whether the promised genetic advancements can translate into functional, deployable assets that meet the stringent requirements of modern military operations.